Table 1.
Baseline Characteristics
| Patients, No. | 368 |
| Variables | |
| Age, mean±SD, y | 60.6±10.8 |
| Women, No. (%) | 198 (52.9) |
| Current smoker, No. (%) | 56 (15.0) |
| Type 2 diabetes mellitus, No. (%) | 75 (20.1) |
| Objective measures | |
| BMI, mean±SD, kg/m2 | 29.5±5.1 |
| 24‐h ambulatory DBP, mean±SD, mm Hg | 77±9 |
| 24‐h ambulatory SBP, mean±SD, mm Hg | 128±13 |
| Fasting glucose, mg/dL, median (Q1–Q3) | 95 (88–107) |
| Total cholesterol, mg/dL, median (Q1–Q3) | 200 (167–227) |
| Triglycerides, mg/dL, median (Q1–Q3) | 111 (77–150) |
| Markers of inflammation, median (Q1–Q3) | |
| Leukocyte count×103/μL | 5.7 (4.8–6.8) |
| Platelet count×103/μL | 228 (196–275) |
| CRP, mg/L | 1.7 (0.9–3.3) |
| 25[OH]D, ng/mL | 28.2 (21.5–36.2) |
| Prior history of CVD, No. (%) | |
| MI | 27 (7.2) |
| Stroke or TIA | 28 (7.5) |
| Atrial fibrillation | 12 (3.2) |
| Medication use, No. (%) | |
| β‐Blockers | 192 (51.3) |
| ACE inhibitors | 132 (35.3) |
| Calcium channel blockers | 98 (26.2) |
| HR measures, mean±SD, beats per min | |
| Daytime HR | 73±10 |
| Nighttime HR | 64±9 |
| 24‐h HR | 71±10 |
Abbreviations: 25[OH]D, 25‐hydroxyvitamin D; ACE, angiotensin‐converting enzyme; BMI, body mass index; CRP, C‐reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; HR, heart rate; MI, myocardial infarction; SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischemic attack; WBC, white blood cell.